We recently demonstrated that the SGLT2 inhibitor dapagliflozin slows breast tumor growth when administered as monotherapy in obese mice, and that its anticancer effect was correlated with its ability to reverse fasting hyperinsulinemia33. This evidence concerns the gene SLC5A2 and breast neoplasm.